Tuesday, November 15th 2016 at IECB, Pessac (Institut Européen de Chimie et Biologie)



The BRIO Scientific Day is an important yearly meeting for the Bordeaux cancer research community. It is an opportunity to find out about the research everyone is doing as well as a key networking opportunity. This year the SIRIC BRIO will highlight some of its investments to reinforce integrated cancer research in Bordeaux.

Programme summary in pdf,or see below


If you can, print the A4 poster and pin it in where your colleagues will see it. Thank you in advance! affiche_journee_scientifique_siricbrio_2016


All PhD students and post-docs funded by the SIRIC BRIO will present a poster, as well as any other local PhD student or post-doc working on cancer who would like to present and discuss their work with the participants of the SIRIC BRIO Scientific Day. Abstracts should be sent to n.caplet@bordeaux.unicancer.fr on November 2nd at the latest. Two abstracts will be selected and the corresponding research will be presented in a short talk at the SIRIC BRIO Scientific Day (you will be informed on Nov 8th). Posters will be featured all day and partipants will select the best one over lunchtime. Prizes (100€ book vouchers) will be given to the 3 winners.  More information : call-for-posters-2016 (Please inform PhD students and post-docs around you. Thank you)

Most of the projects funded via SIRIC BRIO calls for proposals will be featured in oral presentations (see programme below).

At the end of the afternoon, after a presentation on the link between patient associations and research at national and international levels in the case of sarcomas, the concluding session will allow the audience to discuss and reflect on the present and future of cancer translational research, with the outlook of some members of BRIO’s Scientific Advisory Board.

See programme below the photo



Programme (most presentations will be in English):

8:30-9:00    Coffee and registration

9:00–9:30  SIRIC BRIO presentation and new developments

Pierre Soubeyran – SIRIC BRIO director – Professeur des universités et Praticien Hospitalier

9:30 – 10:05     Tumor genetics and pathology research
Chairman : Frédéric Elustondo, head of Project Management

Implication of effector T-cells in chronic lymphoid leukemia (CLL) –Dorothée Duluc, Maitre de conférences, Université de Bordeaux / CNRS UMR 5164 ImmunoConcEpT

Non-invasive monitoring of targeted therapy using circulating tumour DNA in blood from Cancer Patients included in the Bergonie Institute Profiling (BIP) Program – Isabelle Soubeyran, médecin, responsable unité de pathologie moléculaire, Bergonié Institut

10:05 – 10:50    Research in Paramedical and Nursing Sciences within the cancer field

Chairman: Nathalie Caplet, Scientific Communication Manager, SIRIC BRIO

Adaptation de la Plateforme québécoise d’Echange de Savoirs « PES » entre soignants et patientes : Etude des freins et facteurs à son utilisation dans le cas de femmes atteintes d’un cancer du sein en Aquitaine – Hélène Hoarau, Ethnologue – Anthropologue de la santé – Laboratoire ADES CNRS – Bordeaux University Hospital

Analyser les interventions des Infirmières de Coordination en Cancérologie dans les parcours complexes des patients atteints de cancer en région Aquitaine-Limousin-Poitou-Charentes – Marie-Noëlle Gombert, Infirmière de Coordination en Cancérologie – CHU de Bordeaux – Centre de Coordination du Cancer

Etude de l’impact d’une Séance d’Hypnose Formelle Préopératoire sur l’anxiété péri opératoire de patientes hospitalisées pour hystérectomie liée à un cancer gynécologique pelvien – Jenny Sourzac, Infirmière – CHU de Bordeaux -Service de chirurgie gynécologique

Consultation psychologique d’Acccompagnement Professionnel en ONCOlogie (Cap’Onco) – Guilaine WilkinsAssistante sociale – et Véronique Gérat-Mullerpsychologue – Bergonié Institute

10:50 – 11:15    Coffee break,networking and poster review

11:15 – 12:05     Humanities and social sciences in the cancer research field
Chairman : Pierre Soubeyran, SIRIC BRIO Director– Professeur des universités et Praticien Hospitalier

Les impacts des innovations scientifiques en génomique sur les espaces professionnels et la prise en charge des patients –Béatrice Jacques – Maitre de conférences – University of Bordeaux / CNRS UMR 5116

Processus décisionnel à l’égard du traitement médical du cancer en contexte polypathologique et vécu de la décision : des expériences de patients âgés – Annick Tijou Traore, anthropologue, chercheur contractuelle rattachée à l’équipe ADES/SSD, Institut d’études politiques de Bordeaux / CNRS UMR 5115

ImpAct de la sitUaTion sOcio-écoNOmique des Malades atteints de cancer du rein sur la qualité de viE et leur place dans la prise en charge médicale – David Saint-Marc, docteur en sociologie chercheur associé centre Emile Durkheim, Université de Bordeaux

12:05 – 12:30  Health outcomes Research and Epidemiology in the South West

Geriatric syndromes and cancer incidence and death in elderly people GESYCA – Jean-François Dartigues, Professeur des universités et Praticien Hospitalier, University of Bordeaux

Surrogate endpoints for overall survival in adjuvant breast cancer: a meta-analysis of randomized controlled trials. Marion Savina, doctorante, INSERM U1219

12:30 – 14:00   Lunch and poster review

14:00 – 15:30    Translational research projects

Chairman: Paolo Meoni, General Manager, SIRIC BRIO

Presentation of the 4 projects selected via the Bench to Bedside and Back-Prog Call for proposals

Immune checkpoint in Chronic and Acute Myeloid Leukemia – A new target – Pierre-Yves Dumas, Doctorant, Bordeaux University Hospital, Inserm U1035

Biomarkers of Ageing for the assessment of frailty in Cancer of Older patients – Pierre Soubeyran, SIRIC BRIO director – Professeur des universités et Praticien Hospitalier

Role of protein precursors maturation by the convertases in colon cancer: A new prognostic and therapeutic strategy – Abdel-Majid Khatib, Directeur de recherche, Inserm U1029

CANcer et Expositions aux Pesticides Agricoles : de la compréhension des pratiques à la prévention des cancers/ Cancer and Exposures to pesticides in Agriculture: from understanding practices to cancer prevention – Isabelle Baldi (to be confirmed)- Maitre de conférences et Praticien Hospitalier, Inserm U1219

Presentation of 2 projects using the technology supported by the Bench to Bedside and Back-Tech Call for proposals

Membranes – Isabelle Alves, Chargée de Recherche au CNRS- Université de Bordeaux / Institut de Chimie et de Biologie des Membranes et Nano-objets

Oncoprot – Anne-Aurélie Raymond – chef de projets – et Frédéric Saltel chargé de recherches- Inserm U1053 – BaRITOn

15:30 – 16:00     Poster competition / 2 oral presentations (winners on poster abstracts)

Chairman: Paolo Meoni, General Manager, SIRIC BRIO

Presentation of the 2 PhD students awarded for best abstract and announce of the best poster

Hematopoietic niche sustains FLT3-ITD AML blasts through AXL activation by cytokine/growth factor – Pierre-Yves Dumas, Doctorant CHU de Bordeaux / Inserm U1035

Disease characteristics, socioeconomic status, place of care and survival in a population-based cohort of elderly patients with non-Hodgkin lymphoma – Sandra Leguyader Peyrou, épidémiologiste, Registre des Hémopathies malignes de la Gironde- INSERM U1219 équipe EPICENE

16:00-16:30 Coffee Break and Networking

16:30-17:00 Novel oncogenic mechanisms in lung adenocarcinoma

David Santa-Maria – New group leader associate at the IECB

Chairman : Pierre Soubeyran, SIRIC BRIO Director– Professeur des universités et Praticien Hospitalier

Research Project: We have recently utilized mouse models to study the very early stages of lung adenocarcinoma. This approach bypassed the difficulties imposed by tumour heterogeneity in full-blown tumours and also facilitated the identification of novel therapeutic targets with low toxicity and potential clinical applicability.

Our study also revealed that cancer cell fate and tumour malignancy are established at an unanticipated early step. We plan to continue using mouse models and tissue organoids to identify and investigate novel signalling pathways and oncogenic functions that govern the onset of lung adenocarcinoma.

Our approach will have special emphasis on the identification of novel factors implicated in the negative feedback of the MAPK pathway given the essential role of this signalling route in tumour progression and the emergence of resistance to targeted therapies.

Finally, we also intend to pay particular attention to the significant percentage (up to 40 %) of lung adenocarcinoma patients without identified oncogenic driver to potentially translate this knowledge into novel therapeutic treatments.

Biography: David Santamaría received his PhD from University Autónoma of Madrid (Spain) in 1999, under the guidance of Prof. Jorge B. Schwartzman, studying replication fork barriers. He then joined the laboratory of Prof. Ronald A. Laskey, (1999-2003) at the Wellcome/CRC Institute (Cambridge, UK) where he dealt with the initiation of DNA replication and its connection with cell cycle control. He returned to Spain (2003-2016) as a staff scientist in Prof. Mariano Barbacid group (CNIO, Madrid) where he has used mouse genetics to conduct a comprehensive analysis of the Cyclin Dependent Kinase family and to identify putative therapeutic targets in lung adenocarcinoma.

He was recently recruited as a group leader at the IECB to continue his research on novel oncogenic pathways and signalling mediators in lung adenocarcinoma.

17:00-18:00    Construire la recherche et la prise en charge du cancer avec les patients

Chairman: Nathalie Caplet, SIRIC BRIO

Jean-Michel Coindre –Professeur des universités et Praticien Hospitalier – Bergonié Institute, présente Estelle Lecointe, Présidente d’Info Sarcomes and Sarcoma Patients EuroNet (SPAEN)

Présidente-Fondatrice de l’association française des patients du GIST« Ensemble contre le GIST » créée en 2005 à la suite de son propre diagnostic, Estelle LECOINTE-ARTZNER fonde, en 2009, avec l’aide de quelques médecins, l’association “Info Sarcomes” afin de promouvoir la connaissance de ces cancers rares et d’améliorer leur prise en charge sur le territoire. Afin d’étendre ces objectifs à l’ensemble de la communauté européenne, elle fonde la même année, avec ses homologue Européen, la coalition associative “Sarcoma Patients Euro Net” dont elle est Présidente depuis 2014.

Estelle LECOINTE-ARTZNER est également membre du COMité des usagers et des professionnels de l’INCa depuis 2008 et siège au sein du Conseil Scientifique International de l’INCa depuis 2013.

Round-table discussion with scientists from the SIRIC BRIO community, members of the BRIO’s Scientific Advisory Board and the audience


Nathalie Caplet – SIRIC BRIO scientific communication manager
+33 (0) 624 27 60 09 – n.caplet@bordeaux.unicancer.fr

Avec le soutien de :



Sanofi Pasteur - CMJN - Colors